<p>Abbreviations: MTA-ERC, medial temporal areas including the entorhinal cortex; WBC, whole brain cortices. Left panel shows change in MTA-ERC and WBC volumes before and after the 6-month intervention. Solid and dashed lines indicate the exercise and control groups, respectively. Group mean differences and standard errors for MTA-ERC and WBC atrophy are shown in panels A and B, respectively, for all subjects. Panels C and D show mean differences and standard errors for MTA-ERC and WBC atrophy, respectively, for older adults with aMCI. The repeated-measures ANOVA revealed that there was a significant group × time interaction on WBC atrophy level (<i>p</i><.05) in older adults with aMCI. Right panel shows typical images for VSRAD, indicated ...
OBJECTIVE: To assess the time course of brain atrophy and the difference across clinical subtypes in...
<p>Comparison of the baseline activity (upper row) with the post HBOT activity (middle row) and the ...
Cerebral atrophy rate is increasingly used as an outcome measure for Alzheimer's disease (AD) trials...
Background: MCI is a transitional period between normal ageing and clinically probable early Alzheim...
<p><b>Evolution of the percentage brain volume change up to 48 months (A), from 12 to 48 months (B),...
Brain atrophy, thought to reflect neuroaxonal degeneration, may be considered an objective marker of...
OBJECTIVE: To describe the dynamics of brain volume loss (BVL) at different stages of relapsing-remi...
The effects of age, subcortical vascular disease, apolipoprotein E (APOE) epsilon 4 allele and hyper...
<p>Percentage changes in mean brain volume in patients with relapsing-remitting multiple sclerosis r...
<p>Results of the between group MTI analysis adjusted for atrophy [p<0.05 FWE corrected for multiple...
Cerebral atrophy rate is increasingly used as an outcome measure for Alzheimer\u27s disease (AD) tri...
Here, we report the effects of a 6-month aerobic walking and dance interventions (clinical trial NCT...
Several magnetic resonance imaging studies have shown that the entorhinal cortex (ERC) is the first ...
<p>(A) Percentage change in brain volume over one year in subject groups. (B) Voxelwise within-group...
Objective: To determine whether 24 weeks of high-intensity progressive aerobic exercise (PAE) affect...
OBJECTIVE: To assess the time course of brain atrophy and the difference across clinical subtypes in...
<p>Comparison of the baseline activity (upper row) with the post HBOT activity (middle row) and the ...
Cerebral atrophy rate is increasingly used as an outcome measure for Alzheimer's disease (AD) trials...
Background: MCI is a transitional period between normal ageing and clinically probable early Alzheim...
<p><b>Evolution of the percentage brain volume change up to 48 months (A), from 12 to 48 months (B),...
Brain atrophy, thought to reflect neuroaxonal degeneration, may be considered an objective marker of...
OBJECTIVE: To describe the dynamics of brain volume loss (BVL) at different stages of relapsing-remi...
The effects of age, subcortical vascular disease, apolipoprotein E (APOE) epsilon 4 allele and hyper...
<p>Percentage changes in mean brain volume in patients with relapsing-remitting multiple sclerosis r...
<p>Results of the between group MTI analysis adjusted for atrophy [p<0.05 FWE corrected for multiple...
Cerebral atrophy rate is increasingly used as an outcome measure for Alzheimer\u27s disease (AD) tri...
Here, we report the effects of a 6-month aerobic walking and dance interventions (clinical trial NCT...
Several magnetic resonance imaging studies have shown that the entorhinal cortex (ERC) is the first ...
<p>(A) Percentage change in brain volume over one year in subject groups. (B) Voxelwise within-group...
Objective: To determine whether 24 weeks of high-intensity progressive aerobic exercise (PAE) affect...
OBJECTIVE: To assess the time course of brain atrophy and the difference across clinical subtypes in...
<p>Comparison of the baseline activity (upper row) with the post HBOT activity (middle row) and the ...
Cerebral atrophy rate is increasingly used as an outcome measure for Alzheimer's disease (AD) trials...